{"id":750200,"date":"2023-04-24T07:34:20","date_gmt":"2023-04-24T11:34:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\/"},"modified":"2023-04-24T07:34:20","modified_gmt":"2023-04-24T11:34:20","slug":"promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\/","title":{"rendered":"ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer\u2019s Disease and ALS at American Academy of Neurology Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>\n          <em>Lead therapeutic candidate for Alzheimer\u2019s disease, PMN310, demonstrate<\/em><br \/>\n          <em>d<\/em><br \/>\n          <em> selective binding and protection against toxic amyloid-beta <\/em><br \/>\n          <em>oligomers<\/em>\n        <\/li>\n<li>\n          <em>Preclinical data support misfolded RACK1 as a potential target for ALS and FTLD-TDP<\/em>\n        <\/li>\n<\/ul>\n<p>TORONTO, Ontario and CAMBRIDGE, Massachusetts, April  24, 2023  (GLOBE NEWSWIRE) &#8212; ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer\u2019s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced data supporting the receptor of activated C-kinase 1 (RACK1) as a potential target in ALS and frontotemporal lobar degeneration with TPD-43-immunoreactive pathology (FTLD-TDP), and updated preclinical data from the Company\u2019s lead candidate for AD, PMN310. The data were presented in poster presentations on April 23 at the 75th American Academy of Neurology (AAN) Annual Meeting in Boston, MA.<\/p>\n<p>\u201cWe are pleased to share progress highlighting our ongoing effort to develop next-generation therapies for debilitating neurodegenerative disorders,\u201d said Gail Farfel, Ph.D., Chief Executive Officer of ProMIS Neurosciences. \u201cWe are excited to share the data differentiating our lead therapeutic candidate for Alzheimer\u2019s disease, PMN310, which exhibited characteristics in preclinical studies that may provide greater therapeutic potential and support a favorable tolerability profile compared to other amyloid-beta antibodies. AAN is also a great opportunity to present our data supporting the potential of misfolded RACK1 as a novel target for ALS and also FTLD-TDP, and our ability to generate antibodies that selectively bind aggregated RACK1 while avoiding benign isoforms.\u201d<\/p>\n<p>\n        <strong><br \/>\n          <u>AAN Poster Details<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Title:<\/strong> Protection Against Toxic Amyloid-beta Oligomers by PMN310, a Monoclonal Antibody Rationally Designed for Greater Therapeutic Potency in Alzheimer\u2019s Disease<br \/><strong>Session<\/strong><strong>: <\/strong>P1: Aging and Dementia: Basic Science (abstract #4597) <br \/><strong>Presenter: <\/strong>Johanne Kaplan, Ph.D.<br \/><strong>Date <\/strong><strong>&amp;<\/strong><strong> Time:<\/strong> April 23, 2023 from 8:00 \u2013 9:00 a.m. ET<\/p>\n<p>Evidence suggests that soluble toxic amyloid-beta (A\u03b2) oligomers, rather than A\u03b2 monomers or plaque, are a primary driver of synaptic dysfunction, neuronal loss and cognitive decline in AD patients. However, it is difficult to specifically target toxic oligomers since they are much less abundant than other forms of A\u03b2 in the brain. In the poster presented, clinical activity of various A\u03b2 antibodies was shown to correlate with the ability to avoid monomer competition and retain binding to AD brain toxic oligomers. ProMIS\u2019 lead therapeutic candidate, PMN310, showed selective binding to oligomers and was the least impacted by monomer competition compared to other A\u03b2-directed antibodies. Additionally, PMN310\u2019s lack of binding to A\u03b2 plaque observed in preclinical studies may reduce the risk of brain edema and microhemorrhages (ARIA) associated with plaque-binding antibodies. PMN310 protected memory function in two rodent models of AD, supporting further evaluation of the candidate as a potential therapeutic option for the treatment or prevention of AD.<\/p>\n<p>\n        <strong>Title:<\/strong> RACK1 Knockdown Is a Potential Therapeutic Target in ALS and FTLD-TDP<br \/><strong>Session<\/strong><strong>: <\/strong>P1: Aging and Dementia: Basic Science (abstract #3494)<br \/><strong>Presenter: <\/strong>Neil Cashman, M.D.<br \/><strong>Date <\/strong><strong>&amp;<\/strong><strong> Time:<\/strong> April 23, 2023 from 8:00 \u2013 9:00 a.m. ET<\/p>\n<p>ProMIS has evaluated RACK1 as a potential target for ALS and FTLD-TDP. These neurodegenerative disorders are characterized by the formation of pathogenic aggregates of misfolded TAR DNA binding protein 43 (TDP-43) inside neurons which have been observed to co-aggregate with misfolded RACK1, a ribosomal protein. In a cell system, the misfolded form of RACK1 was detected by ProMIS antibodies selective for this RACK1 isoform.<\/p>\n<p>The poster presented describes how RACK1 knockdown was able to reduce TDP-43 aggregation as well as alleviate the TDP-43-induced global suppression of translation <em>in vitro<\/em>. Knocking down RACK1 also reduced retinal and motor neuron neurodegeneration in D. melanogaster <em>in vivo<\/em>. These preclinical findings support misfolded RACK1 as a potential therapeutic target for TDP-43 proteinopathy in non-SOD1 and non-FUS ALS as well as FTLD-TDP.<\/p>\n<p>Both poster presentations are available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mfpyPrijNFz5bijYd9eaPOsEG73B-Q-9tO_5FuSRaztwYDUiDUx93EZ_zDsmGPdConRxLJA54QUp2UVEdysa0k_XVjyID29EYdR_xqg7zNtRwhWxmhU89MC88srkhaqqcxpMod0qC6pE8A6JW7us8A==\" rel=\"nofollow noopener\" target=\"_blank\">Poster and<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JhAzr6KQD2u3pvdfAfqBnvL0wEVIq9Xw6jvMlU4YaZb2mi7r1YkmZY4phoqi1HJgtKmmzzDRYGWMEOpekbr-1wtsdH1sWNmqgP7Nb9yFm3rSCB_4WgIjo95LrvifwwfYZ2GPMycAmS46RT2hTijBNg==\" rel=\"nofollow noopener\" target=\"_blank\">Publications<\/a> page of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LbN1CjxYCHkkTLimNa35dQ1yN8cc6hLo7E-XGz7d-ChV4qWJm6NmFWKceLx48G2JYBum18I0rLZgKVmOM-EWLyTotJr8OgEBaS0ff9CXEwc=\" rel=\"nofollow noopener\" target=\"_blank\">www.promis<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YMpI1_ESt1QlNgyCJS7btlwoPIaCdUuQq9eJq_dg-iiFaHFsV7NV6py647HOIM_YbN_PJeI80xgOL1q0EbpzqQ==\" rel=\"nofollow noopener\" target=\"_blank\">n<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kdIoubtTcZ-ZzEX82eF3vzKb9nBtIZYyPPJsTqlIuZljR9WWGNeaAQxQoSnWqcR3r6oPgrLPAcydY5DPq8L5DVULtbWjhAJYducDiK7PuQM=\" rel=\"nofollow noopener\" target=\"_blank\">eurosciences.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About ProMIS Neurosciences Inc.<\/strong>\n      <\/p>\n<p>ProMIS Neurosciences Inc. is a development stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer\u2019s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company\u2019s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform &#8211; ProMIS\u2122 and Collective Coordinates &#8211; to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts. ProMIS is listed on Nasdaq and the Toronto Stock Exchange under the symbol PMN.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>Neither the TSX nor Nasdaq has reviewed and neither accepts responsibility for the adequacy or accuracy of this release.\u00a0Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, \u200e\u200e\u201cforward-looking information\u201d) within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the \u200euse of forward-looking terminology such as \u201cplans\u201d, \u201ctargets\u201d, \u201cexpects\u201d or \u201cdoes not expect\u201d, \u201cis expected\u201d, \u201can opportunity exists\u201d, \u200e\u200e\u201cis positioned\u201d, \u201cestimates\u201d, \u201cintends\u201d, \u201cassumes\u201d, \u201canticipates\u201d or \u201cdoes not anticipate\u201d or \u201cbelieves\u201d, or variations of such words and \u200ephrases or state that certain actions, events or results \u201cmay\u201d, \u201ccould\u201d, \u201cwould\u201d, \u201cmight\u201d, \u201cwill\u201d or \u201cwill be taken\u201d, \u201coccur\u201d or \u201cbe \u200eachieved\u201d. In addition, any statements that refer to expectations, projections or other characterizations of future events or \u200ecircumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to targeting of toxic misfolded proteins that the Company believes may directly address fundamental AD pathology (including the belief and understanding that toxic oligomers of amyloid-beta are a major driver of AD) and have greater therapeutic potential due to reduction of off-target activity, ProMIS\u2019 pipeline, management\u2019s belief that its patented platform technology has created an antibody candidate specific to toxic misfolded oligomers known to be present in Alzheimer\u2019s disease, and management\u2019s belief that this specificity may indicate greater therapeutic potential due to lower off-target activity and reduce the risk of brain edema and microhemorrhages (ARIA) associated with plaque-binding antibodies, and the potential of misfolded RACK1 as a potential therapeutic target. Statements containing forward-looking\u00a0information are not historical facts but instead represent management&#8217;s current \u200eexpectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events \u200eand trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to \u200eknown and unknown risks, uncertainties and assumptions and other factors that may cause the actual results, level of activity, \u200eperformance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the Company\u2019s ability to fund its operations and continue as a going concern, its accumulated deficit and the expectation for continued losses and future financial results. Important factors that could cause actual results to differ materially from those indicated in the forward-looking information include, among others, the factors discussed throughout the \u201cRisk Factors\u201d section of the Company&#8217;s most recently filed annual information form available on www.SEDAR.com, in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2022 and the section entitled \u201cRisk Factors\u201d in its Post-Effective Amendment No. 1 to Form S-1, filed March 17, 2023, each as filed with the Securities and Exchange Commission. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.<\/p>\n<p align=\"justify\">For further information:<\/p>\n<p align=\"justify\">Visit us at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LbN1CjxYCHkkTLimNa35ddfEbAIvWsJvbaIzDBnd2fjnsUsCdU1LkrxYiVUtHaDR4jaZ2fPqaML2rXOQqvy1UHKnhunE1XafoEBLwQx6pkz_udWUdvsxbkndqDxtpzlD\" rel=\"nofollow noopener\" target=\"_blank\">www.promisneurosciences.com<\/a><\/p>\n<p align=\"justify\">Please submit media inquiries to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1l-5uOZcJs6_Em90NG80RPDnG4IXztgiAxt_3YwHvwjzXz1txtIdV0zJPmbWkktlwjVJfEYQgJx3a14dcXLNqFOXPhzTID_oO8-1OqlvHe4d0s-vvWpwc4ik-aDeZQB3\" rel=\"nofollow noopener\" target=\"_blank\">info@promisneurosciences.com<\/a>.<\/p>\n<p align=\"justify\">For Investor Relations, please contact: <br \/>Stern Investor Relations<br \/>Suzanne Messere, Managing Director<br \/>suzanne.messere@sternir.com<br \/>Tel. 212-698-8801<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyMzUyMyM1NTUxODcxIzIwODQ1ODk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NmU0NTNmZTgtZjhiOC00YjFmLWFlZjYtNzhlNzk0OTA1ZmY4LTEwOTYxNjA=\/tiny\/ProMIS-Neurosciences-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lead therapeutic candidate for Alzheimer\u2019s disease, PMN310, demonstrate d selective binding and protection against toxic amyloid-beta oligomers Preclinical data support misfolded RACK1 as a potential target for ALS and FTLD-TDP TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 24, 2023 (GLOBE NEWSWIRE) &#8212; ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer\u2019s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced data supporting the receptor of activated C-kinase 1 (RACK1) as a potential target in ALS and frontotemporal lobar degeneration with TPD-43-immunoreactive pathology (FTLD-TDP), and updated preclinical data from the Company\u2019s lead candidate for AD, PMN310. The data &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer\u2019s Disease and ALS at American Academy of Neurology Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-750200","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer\u2019s Disease and ALS at American Academy of Neurology Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer\u2019s Disease and ALS at American Academy of Neurology Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Lead therapeutic candidate for Alzheimer\u2019s disease, PMN310, demonstrate d selective binding and protection against toxic amyloid-beta oligomers Preclinical data support misfolded RACK1 as a potential target for ALS and FTLD-TDP TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 24, 2023 (GLOBE NEWSWIRE) &#8212; ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer\u2019s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced data supporting the receptor of activated C-kinase 1 (RACK1) as a potential target in ALS and frontotemporal lobar degeneration with TPD-43-immunoreactive pathology (FTLD-TDP), and updated preclinical data from the Company\u2019s lead candidate for AD, PMN310. The data &hellip; Continue reading &quot;ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer\u2019s Disease and ALS at American Academy of Neurology Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-24T11:34:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyMzUyMyM1NTUxODcxIzIwODQ1ODk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer\u2019s Disease and ALS at American Academy of Neurology Annual Meeting\",\"datePublished\":\"2023-04-24T11:34:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\\\/\"},\"wordCount\":1338,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyMzUyMyM1NTUxODcxIzIwODQ1ODk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\\\/\",\"name\":\"ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer\u2019s Disease and ALS at American Academy of Neurology Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyMzUyMyM1NTUxODcxIzIwODQ1ODk=\",\"datePublished\":\"2023-04-24T11:34:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyMzUyMyM1NTUxODcxIzIwODQ1ODk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyMzUyMyM1NTUxODcxIzIwODQ1ODk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer\u2019s Disease and ALS at American Academy of Neurology Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer\u2019s Disease and ALS at American Academy of Neurology Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer\u2019s Disease and ALS at American Academy of Neurology Annual Meeting - Market Newsdesk","og_description":"Lead therapeutic candidate for Alzheimer\u2019s disease, PMN310, demonstrate d selective binding and protection against toxic amyloid-beta oligomers Preclinical data support misfolded RACK1 as a potential target for ALS and FTLD-TDP TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 24, 2023 (GLOBE NEWSWIRE) &#8212; ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer\u2019s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced data supporting the receptor of activated C-kinase 1 (RACK1) as a potential target in ALS and frontotemporal lobar degeneration with TPD-43-immunoreactive pathology (FTLD-TDP), and updated preclinical data from the Company\u2019s lead candidate for AD, PMN310. The data &hellip; Continue reading \"ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer\u2019s Disease and ALS at American Academy of Neurology Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-24T11:34:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyMzUyMyM1NTUxODcxIzIwODQ1ODk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer\u2019s Disease and ALS at American Academy of Neurology Annual Meeting","datePublished":"2023-04-24T11:34:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\/"},"wordCount":1338,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyMzUyMyM1NTUxODcxIzIwODQ1ODk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\/","name":"ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer\u2019s Disease and ALS at American Academy of Neurology Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyMzUyMyM1NTUxODcxIzIwODQ1ODk=","datePublished":"2023-04-24T11:34:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyMzUyMyM1NTUxODcxIzIwODQ1ODk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyMzUyMyM1NTUxODcxIzIwODQ1ODk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-presents-preclinical-data-highlighting-targeting-of-toxic-misfolded-proteins-in-alzheimers-disease-and-als-at-american-academy-of-neurology-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer\u2019s Disease and ALS at American Academy of Neurology Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/750200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=750200"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/750200\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=750200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=750200"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=750200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}